Results 131 to 140 of about 1,158,425 (219)

IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4⁺ T-cell responses. [PDF]

J Immunother Cancer
Guo Y, Wang M, Xuan Y, Pan L, Yan W, Cheng J, Yu Y, Wang X, Xu L, Sun X, Han R, Si L, Wang Y, Li S, Wang P.   +14 more
europepmc   +1 more source

J2R/F4L deleted oncolytic vaccinia virus synergizes with tumor specific killer (ELANE) promotes antitumor immunity with superior safety. [PDF]

Front Immunol
Huang Y, Wang L, Mei S, Zhao F, Wang L, Xie Y, Gao Z, Wang J, Kong Z, He Y, Shi Y, Guo W, Ai B, Fang J, Xu F, Guo F.   +15 more
europepmc   +1 more source

An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma. [PDF]

iScience
Pan L, Zhu X, Zhang J, Zhong Q, Wu H, Sun W, Xia Y, Wang S, Tong X.   +8 more
europepmc   +1 more source

Harnessing oncogenic signaling to enhance oncolytic virotherapy: Lessons from EPAC-encoding vaccinia virus. [PDF]

Mol Ther Oncol
Boulton S, Singh S, Bell JC.
europepmc   +1 more source

Oncolytic Vaccinia Virus-Engineered EVs Convert Tumor-Promoting Macrophages into Anti-Tumor Effectors. [PDF]

Cancer Manag Res
Chen L, Ye L, Bao L, Wang J, Tan M.
europepmc   +1 more source

Thyroid hormone deficiency worsens outcomes in vaccinia virus infection. [PDF]

J Virol
Notario L, Guerrero-Espinosa E, Nistal M, Lauzurica P, Aranda A, Alemany S.   +5 more
europepmc   +1 more source

Identification and evaluation of novel intergenic sites in the vaccinia virus genome for transgene insertion. [PDF]

Mol Ther Oncol
Bueno-Merino C, Del Canizo A, Conesa M, Barcia M, Sallent I, Manils J, Forcales SV, Soler C, Rojas JJ.   +8 more
europepmc   +1 more source

Safety and immunogenicity of a first-generation modified vaccinia virus Ankara-vectored SARS-CoV-2 vaccine candidate with mRNA-based booster vaccination: A phase 1 trial. [PDF]

Hum Vaccin Immunother
Fathi A, Dahlke C, Mayer L, Mellinghoff SC, Krähling V, Halwe S, Müller-Kräuter H, Fendel R, Kremsner P, Esen M, Klug M, Lütgehetmann M, Weskamm LM, MVA-SARS-2-S Study Group, Sutter G, Becker S, Hardtke S, Addo MM.   +17 more
europepmc   +1 more source

Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines. [PDF]

Sci Rep
Kim JH, Kim Y, Shin Y, Park I, Kwon WS, Kim TS, Lee N, Oh K, Kim C, Jeung HC, Rha SY.   +10 more
europepmc   +1 more source

IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma. [PDF]

Cancer Immunol Immunother
Wu H, Zhang J, Xu L, Xie Y, Pan L, Zhang X, Xia Y, Yang F, Kang X, Tong X, Wang S.   +10 more
europepmc   +1 more source